Attention Laurel Patients:  The new Laurel office is open. The address is 7140 Contee Road, Suite 3500, Laurel, MD 20707….Attention Lanham Patients: Our new Largo office will be opening Monday,  June 17th and our Lanham location will be closed permanently. Largo’s address is 9333 Healthcare Way Suite 4100 Largo, MD 20774.

Trial Protocol ID
USOR 23229_TTX-030-003

Investigator
Mohit Narang, M.D.

An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab, compared to chemotherapy alone, for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma

Trial Protocol ID
USOR 22133_C-800-22

A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX)

Trial Protocol ID
USOR 22033_TT420C1206 *STAR*

A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma

Trial Protocol ID
USOR 22123_1403-0011_Brightline-2 *STAR*

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

Trial Protocol ID
USOR 22093_XB002-101_Jewel-101

A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (XB002-101)